Alan Litwin, MD

PrintE-mail
Assistant Professor
Diagnostic Imaging
Department of Diagnostic Radiology
Roswell Park Cancer Institute
Clinical Assistant Professor of Radiology
School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise: 
CT-based vascular imaging
Ultrasound
Virtual bronchoscopy
Virtual colonoscopy

Background Information

Education and Training: 
MD - University of Toledo, College of Medicine (Formerly Medical College of Ohio) Toledo, OH
Residency: 
Mt. Sinai Medical Center, Cleveland, OH
Board Certification: 
Diagnostic Radiology, American Board of Radiology

Publications

Publications: 
  • Fakih MG, Wang K, Holleran JL, Litwin A, Zwiebel JA, Espinoza-Delgado I, Muindi JR, Egorin MJ, Fetterly G, Diasio RB. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clinical cancer research 2010; 16(14):3786-3794
  • Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding GE, Teh BT, Kim HL. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. Journal of urology 2010; 184(3):859-864
  • Khushalani NI, Fetterly GJ, Iyer RV, Litwin A, Brady W, Javle MM. Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers. Journal of clinical oncology 2010; 28(15 Suppl.):TPS201
  • Iyer RV, Fakih M, Ma W, Tucker C, Levea C, Starostik P, Litwin A, Tan W, Khushalani NI, Adjei AA. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G) : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract# 258
  • Angitapalli R, Litwin AM, Kumar PRG, Nasser E, Lombardo J, Mashtare T, Wilding GE, Fakih MG. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology 2009; 76(5):363-368
  • Bharthuar A, Pearce L, Litwin A, LeVea C, Kuvshinoff B, Iyer R. Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report. JOP : Journal of the pancreas 2009; 10(5):523-527
  • Chadha MK, Litwin A, Levea C, Iyer R, Yang G, Javle M, Gibbs JF. Surgical resection after TNFerade therapy for locally advanced pancreatic cancer. JOP : Journal of the pancreas 2009; 10(5):535-538
  • Chadha MK, Javle MM, Kuvshinoff B, Gibbs JF, Raczyk C, Litwin A, Wilding GE, Mashtare T, Lombardo J, Iyer RV. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer research 2009; 29(10):4127-4130
  • Fakih MG, Holleran JL, Ross ME, Rustum YM, Litwin A, Espinoza-Delgado I, Zwiebel JA, Toth K, Fetterly G, Pendyala L, Egorin MJ. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clinical cancer research 2009; 15(9):3189-3195
  • Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J, Gibbs J, Iyer R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. British journal of cancer 2009; 100(12):1842-1845
  • Iyer R, Javle M, Robins M, Levea C, Litwin A, Nava H, Tan W, Shefter T, Yang G, Khushalani NI. Phase II multicenter study of erlotinib and radiation therapy (RT) for elderly patients (PTS) with esophageal carcinoma (EC)- final report. Annals of oncology 2010; 21(Suppl. 8):259-260
  • Khushalani NI, Brady W, Fetterly G, Prey J, Levea C, Litwin A, Grande C, Iyer R, Javle M. Continuous and intermittent vorinostat (V) in combination with folfiri in advanced upper gastrointestinal cancer (AUGC): Preliminary results of a phase I pharmacokinetic (PK) study. Annals of oncology 2010; 21(Suppl. 8):260
  • Anne N, Rajput A, Dunn KB, Litwin A. Idiopathic pneumatosis intestinalis of the small intestine. American surgeon 2008; 74(11):1127-1129
  • Gottlieb RH, Litwin A, Gupta B, Taylor J, Raczyk C, Mashtare T, Wilding G, Fakih M. Qualitative radiology assessment of tumor response: does it measure up? . Clinical imaging 2008; 32(2):136-140
  • Lau YK, Chadha MK, Litwin A, Trump DL. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature. Journal of hematology and oncology 2008; 1:21
  • Gupta B, LeVea C, Litwin A, Fakih MG. Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. Clinical colorectal cancer 2007; 6(6):447-449
  • Javle M, Shah P, Yu J, Bhagat V, Litwin A, Iyer R, Gibbs J. Cystic pancreatic tumors (CPT): predictors of malignant behavior. Journal of surgical oncology 2007; 95(3):221-228
  • Sullivan M, Casey DM, Alberico R, Litwin A, Schaaf NG. Hyperostosis in an orbital defect with craniofacial implants and open-field magnets: a clinical report. Journal of prosthetic dentistry 2007; 97(4):196-199
  • Henschke CI; Yankelevitz DF; McCauley DI; Sone S; Hanaoka T; Markowitz S; Miller A; Klingler K; Scherer T; Inderbitzi R; Zulueta J; Montuenga L; Bastarrika G; Giunta S; Crecco M; Pugliese P; Tockman M, International Early Lung Cancer Action Program Investigators, Vafai D, Ottinger M, Sullivan F, Ginsberg MS, Heelan RT, Thurer R, Mendelson DS, Lovett L, Williams HT, Smith MV, Shah R, Khan A, Scalzetti EM, Kohman LJ, Matalon TAS, Odzer S-L, Liu X, Luedke D, Camacho E, Hansen R, Thorsen MK, Rotter A, Grannis F, Kalafer M, Mullen D, Endress C, Pass H, Ray D, Wiernik PH, Cole E, Sheppard B, Loud PA, Litwin A, Crecco M, Giunta S, Bastarrika G, Montuenga L, Zulueta J, Inderbitzi R, Scherer T, Klingler K, Miller A, Markowitz S, Hanaoka T, Sone S, McCauley DI, Yankelevitz DF, Pugliese P, Tockman M, Shaham D, Klippenstein D, Kopel S, Fiore E, Rifkin M, McGuinness G, Naidich D, Pearson GDN, Austin JHM, Lally J, Bauer T, Patsios D, Roberts H, Aye R, Rice K, Henschke CI. Computed tomographic screening for lung cancer: individualising the benefit of the screening. European respiratory journal 2007; 30(5):843-847
  • New York Early Lung Cancer Action Project Investigators, Smith JP, Reeves AP, Pasmantier MW, Ostroff J, Miettinen OS, Libby DM, Faustini Y, Farooqi A, Vazquez MF, Yip R, Travis WD, Noguchi M, Gazdar A, Brambilla E, Carter D, Hess JM, Kramer AL, Agnello KK, Altorki N, Wiernik PH, Matalon TAS, Kopel S, Shiau MC, Pearson GDN, Austin JHM, Fiore ES, Rifkin M, McCauley DI, Yankelevitz DF, Klippenstein D, Litwin A, Ginsberg MS, Heelan RT, Mendelson DS, Shah R, Khan A, Scalzetti EM, Kohman LJ, Loud PA, Henschke CI. CT Screening for lung cancer: diagnoses resulting from the New York Early Lung Cancer Action Project. Radiology 2007; 243(1):239-249
  • Iyer RV, Yang G, Schefter TE, Tan W, Nava HR, Levea C, Litwin A, Robins M, Khushalani NI. Phase II multicenter study of erlotinib with radiation therapy (RT) for elderly patients (pts) with esophageal carcinoma (EC): Final report : 2011 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2011; 29(4 Suppl.):135
  • Chadha M, Chadha K, Lombardo J, Mashtare T, Wilding G, Gibbs J, Kuvshinoff B, Litwin A, Raczyk C, Javle M, Iyer R. Dose Escalation of Octreotide Acetate for Management of Gastro-entero-pancreatic Neuroendocrine Tumors. American journal of gastroenterology 2009; 104(Suppl. 3):S103 (Abstract #268)
  • Fetterly GJ, Brady WE, LeVea CM, Litwin AM, Zagst PD, Prey JD, Tarquini M, Giardina MK, Iyer RV, Khushalani NI. A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15540
  • Iyer R, Khushalani N, Tan W, Litwin A, LeVea C, Hutson A, Tucker C, Ma W, Fakih M, Adjei A. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G). European journal of cancer (Oxford, England : 1990) 2009; 7(2):391
  • Javle M, Yu J, Pande A, Garrett C, Kuvshinoff B, Litwin A, Gibbs J, Iyer R. Bevacizumab in combination with gemcitabine and capecitabine improves quality of life in patients with advanced pancreatic cancer (APC) - final results of the multicenter phase II study. Annals of oncology 2008; 19(Suppl. 6):67
  • Iyer R, Fetterly G, Groman A, Hutson A, Khushalani N, Mohile S, Ashton E, Litwin A, Grande C, Tomaszewski G. Sunitinib and Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma (HCC)- Final Results of a Phase 2 Trial. European journal of cancer (Oxford, England : 1990) 2011; 47(Suppl. 1):S447
  • Ellis CM, Shenoy S, Litwin A, Soehnlein S, Gibbs JF. Effective endovascular stenting of malignant portal vein obstruction in pancreatic cancer. HPB surgery 2009; 2009(0):426436